Iparomlimab and tuvonralimab

Multispecific antibody

Also known as QL1706

Approvedregulatory verdict

Evidence outlook

Approved: Recurrent or refractory cervical carcinoma that progressed on or after platinum-based... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Metastatic Colorectal Cancer · Phase 3 · investigational in the US

Also approved (1)
CN
  • Recurrent or refractory cervical carcinoma that progressed on or after platinum-based chemotherapy (conditional approval; iparomlimab + tuvonralimab, trade name Qibei'an)
NMPA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Metastatic Colorectal Cancer
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07613567 · Fujian Cancer Hospital
2027-01-01 – 2032-12-31 · Locally Advanced Cervical Carcinoma
What this study did
NCT06749899 · Sun Yat-Sen University Cancer Center
2025-05-04 – 2030-12-01 · Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
What this study did
NCT06686576 · Qilu Pharmaceutical Co., Ltd.
2024-12-12 – 2030-12 · Colon Cancer
What this study did
NCT07686640 · Shandong Cancer Hospital and Institute
2026-08-15 – 2030-07-15 · Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy
What this study did
NCT06789796 · Qilu Pharmaceutical Co., Ltd.
2025-02 – 2030-03 · Small-cell Lung Cancer
What this study did
NCT07729605 · Sun Yat-sen University
2026-07-30 – 2029-07-30 · Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
What this study did
NCT07002346 · Tongji Hospital
2025-11-15 – 2029-06-01 · Ovarian Clear Cell Carcinoma
What this study did
NCT05446883 · Qilu Pharmaceutical Co., Ltd.
2022-09-23 – 2025-07-01 · METASTATIC CERVICAL CANCER
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT07866313 · Changhai Hospital
2026-06-01 – 2031-12-01 · MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706
What this study did
NCT07636226 · Sun Yat-sen University
2026-07-30 – 2029-12-30 · Small Cell Lung Cancer
What this study did
NCT05976568 · Qilu Pharmaceutical Co., Ltd.
2023-09-01 – 2027-09-01 · Hepatocellular Carcinoma
What this study did
NCT05576272 · Qilu Pharmaceutical Co., Ltd.
2022-05-19 – 2024-12-30 · Nasopharyngeal Carcinoma
What this study did
Phase 2 (146)
Metastatic Colorectal Cancer
NCT07502014 · Huazhong University of Science and Technology
2026-05-01 – 2029-12-31 · Metastatic Colorectal Cancer (CRC), mCRC
What this study did
NCT07446387 · Jiangsu Cancer Institute & Hospital
2026-05-30 – 2029-12-31 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT07070713 · Fujian Cancer Hospital
2025-07-30 – 2028-08-30 · Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
What this study did
NCT07150247 · Sun Yat-sen University
2025-06-01 – 2028-06-30 · BRAF V600 Colorectal Cancer
What this study did
NCT07009145 · Qianfoshan Hospital
2025-06-27 – 2027-12-31 · Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07379398 · Tianjin Medical University Cancer Institute and Hospital
2026-04-01 – 2031-01-31 · NSCLC
What this study did
NCT07134413 · Guangdong Association of Clinical Trials
2025-08 – 2029-07 · NSCLC
What this study did
NCT07139041 · Chang Chen
2025-10 – 2029-06 · NSCLC (Non-small-cell Lung Cancer)
What this study did
NCT07271602 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-01-30 – 2028-12-31 · Non Small Cell Lung Cancer, Immunotherapy, Radiotherapy, Chemotherapy
What this study did
NCT07416058 · Guangdong Association of Clinical Trials
2026-04-30 – 2028-12-31 · Lung Adenocarcinoma
What this study did
NCT07082179 · Jiangsu Cancer Institute & Hospital
2025-09-04 – 2028-12 · NSCLC
What this study did
NCT07330596 · Anhui Provincial Cancer Hospital
2025-10-30 – 2028-02-28 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07200947 · Zhijie Wang
2025-12-01 – 2028-02-01 · SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT07129161 · Sun Yat-sen University
2025-08 – 2027-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06897046 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-07-30 – 2027-05-25 · Non-small Cell Lung Cancer (NSCLC), II-IIIB
What this study did
NCT05329025 · Qilu Pharmaceutical Co., Ltd.
2022-06-01 – 2024-01-01 · Non-small-cell Lung Cancer
What this study did
Other / comorbidity
NCT06852456 · Qilu Pharmaceutical Co., Ltd.
2025-03 – 2034-12 · Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT07649473 · Fujian Medical University
2026-08-15 – 2033-12-31 · Colon Cancer, Synchronous Liver Metastases
What this study did
NCT07246317 · Tianjin Medical University Cancer Institute and Hospital
2025-12-15 – 2032-12-31 · Breast Cancer
What this study did
NCT07396324 · RenJi Hospital
2026-05-01 – 2031-12 · HR-positive/HER2-negative Breast Cancer
What this study did
NCT07847671 · Tianjin Medical University Cancer Institute and Hospital
2026-10-10 – 2031-10 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT07277972 · Tianjin Medical University Cancer Institute and Hospital
2026-02-15 – 2031-08-31 · RCC, Renal Cell Cancer
What this study did
NCT07882056 · Peking University Cancer Hospital & Institute
2026-10-15 – 2031-08 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07135804 · Second Affiliated Hospital of Nanchang University
2025-09-01 – 2031-04-30 · Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
What this study did
NCT07384416 · Sun Yat-sen University
2026-04-10 – 2031-01-31 · Penile Cancer
What this study did
NCT07165847 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2025-07-23 – 2030-12-31 · Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy, Neoadjuvant Chemoimmunotherapy
What this study did
NCT07315035 · The First Affiliated Hospital with Nanjing Medical University
2026-01-01 – 2030-12-31 · Gastric Cancer Stage III
What this study did
NCT07447570 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-10-15 – 2030-12-31 · Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody
What this study did
NCT07673835 · Obstetrics & Gynecology Hospital of Fudan University
2026-06-06 – 2030-12-31 · Ovarian Cancer
What this study did
NCT07933016 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-12-01 – 2030-12-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07490002 · Changhai Hospital
2026-04-06 – 2030-11-30 · Esophageal Squamous Carcinoma
What this study did
NCT06404463 · Fudan University
2024-05-06 – 2030-11-06 · Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
What this study did
NCT07515469 · Tianjin Medical University Cancer Institute and Hospital
2026-05-30 – 2030-10-30 · HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy
What this study did
NCT07141186 · Tianjin Medical University Cancer Institute and Hospital
2025-10-01 – 2030-10-01 · Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent, Cervical Adenocarcinoma, Cervical Cancer Squamous Cell
What this study did
NCT07738159 · West China Hospital
2026-08-01 – 2030-09-01 · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), QL1706, Lenvatinib, Chemotherapy
What this study did
NCT07940478 · Fujian Cancer Hospital
2027-01-01 – 2030-09-01 · Hepatecellular Carcinoma
What this study did
NCT07160647 · Sir Run Run Shaw Hospital
2025-08-20 – 2030-08-30 · dMMR/MSI-H-type Rectal Adenocarcinoma
What this study did
NCT07741617 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-08-15 – 2030-08-15 · Urologic Neoplasms
What this study did
NCT07101744 · Sun Yat-sen University
2025-10-17 – 2030-07-16 · Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
What this study did
NCT07041788 · Second Affiliated Hospital of Nanchang University
2026-04-28 – 2030-07-09 · Cancer
What this study did
NCT07005583 · Tianjin Medical University Cancer Institute and Hospital
2025-06-30 – 2030-05-20 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT06917092 · Tianjin Medical University Cancer Institute and Hospital
2025-06-16 – 2030-04-30 · Endometrial Adenocarcinoma, Endometrial Cancer
What this study did
NCT06878222 · Obstetrics & Gynecology Hospital of Fudan University
2025-03-15 – 2030-03-31 · Cervical Cancers
What this study did
NCT07205497 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-03-28 – 2030-03-30 · Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer
What this study did
NCT06949111 · Hebei Medical University Fourth Hospital
2025-05-15 – 2030-03 · Colon Cancer
What this study did
NCT07867392 · Ruijin Hospital
2025-02-01 – 2030-02-01 · Gastric Adenocarcinoma
What this study did
NCT07085234 · The First Affiliated Hospital of Xiamen University
2025-07-30 – 2029-12-31 · Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
What this study did
NCT07263360 · Tianjin Medical University Cancer Institute and Hospital
2026-02-01 – 2029-12-31 · BTC
What this study did
NCT07315854 · Beijing Friendship Hospital
2025-11-04 – 2029-12-31 · Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer
What this study did
Phase 1/2 (14)
Non-Small Cell Lung Cancer
NCT07453394 · Qilu Pharmaceutical Co., Ltd.
2026-04 – 2029-02 · Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer
What this study did
Other / comorbidity
NCT07272590 · Qilu Pharmaceutical Co., Ltd.
2025-12-30 – 2031-08 · Metastatic Solid Tumors
What this study did
NCT06766305 · Xiangdong Cheng
2025-03-21 – 2031-06-30 · Gastric Cancers, Esophagogastric Junction Cancers
What this study did
NCT07542717 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-04-10 – 2030-03-31 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT07863869 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-09 – 2029-11-27 · Colorectal Cancer Metastatic to Liver
What this study did
NCT07256782 · Qilu Pharmaceutical Co., Ltd.
2025-10-24 – 2028-05 · Advanced Solid Tumor
What this study did
NCT06941766 · Peking Union Medical College Hospital
2025-04-15 – 2028-04-16 · Intermediate Trophoblastic Tumor
What this study did
NCT07291947 · Wang Xin
2025-11-04 – 2027-09-10 · Cholangiocarcinoma
What this study did
NCT06809530 · Guangzhou Medical University
2025-03-17 – 2027-09-01 · Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4, Solid Tumors
What this study did
NCT06746961 · The First Affiliated Hospital of Zhengzhou University
2025-01 – 2027-08 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT07131345 · National Cancer Center, China
2025-09-01 – 2027-07-01 · Malignant Mesothelioma, Mesothelioma
What this study did
NCT05262413 · Qilu Pharmaceutical Co., Ltd.
2022-02-28 – 2024-07-30 · Advanced Renal Cell Carcinoma
What this study did
NCT05603039 · Qilu Pharmaceutical Co., Ltd.
2021-07-01 – 2023-12-30 · Advanced Liver Cancer
What this study did
Phase 1 (6)
Other / comorbidity
NCT06931873 · Changhai Hospital
2025-05-20 – 2035-03-01 · Rectal Cancer
What this study did
NCT07178171 · Xijing Hospital
2025-11-06 – 2030-08-01 · TNBC, Triple Negative Breast Cancer
What this study did
NCT07343791 · JIANG LONGWEI
2025-11-19 – 2027-11-30 · DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy, Iparomlimab and Tuvonralimab Injection
What this study did
NCT06822985 · Wan-Guang Zhang
2025-02-01 – 2026-08-01 · HCC - Hepatocellular Carcinoma
What this study did
NCT04296994 · Qilu Pharmaceutical Co., Ltd.
2020-03-31 – 2023-12 · Advanced Malignant Tumor
What this study did
NCT05171790 · Qilu Pharmaceutical Co., Ltd.
2021-01-11 – 2023-12 · Advanced Solid Tumors
What this study did
Phase 4 (4)
Other / comorbidity
NCT07668570 · Hebei Medical University Fourth Hospital
2026-07 – 2030-07 · HCC - Hepatocellular Carcinoma
What this study did
NCT07854522 · Peking University Cancer Hospital & Institute
2026-10 – 2030-06 · Melanoma, Acral Melanoma
What this study did
NCT07502027 · Huazhong University of Science and Technology
2026-06-01 – 2029-06-30 · Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07004335 · Hebei Medical University Fourth Hospital
2025-07-01 – 2029-01-31 · PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, Bevacizumab
What this study did
Early phase / not applicable (10)
Metastatic Colorectal Cancer
NCT07874438 · The First Affiliated Hospital with Nanjing Medical University
2026-10-08 – 2029-12-31 · Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07452003 · Peking Union Medical College Hospital
2026-01-03 – 2029-12 · Non-Small Cell Lung Cancer
What this study did
NCT07538193 · Tang-Du Hospital
2026-05 – 2029-12 · Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
What this study did
Other / comorbidity
NCT07622836 · The First Affiliated Hospital with Nanjing Medical University
2026-06-05 – 2030-12-31 · TNBC, Adjuvant Therapy, Lymph Node Positive
What this study did
NCT07769853 · Zhejiang University
2026-09-01 – 2029-12-12 · Locally Advanced Rectal Cancer (LARC), 5-12cm to Anal Verge
What this study did
NCT07268131 · Fudan University
2025-12-09 – 2029-10-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07187674 · Harbin Medical University
2025-12-30 – 2028-12-31 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT07546383 · The Second Affiliated Hospital of Hainan Medical University
2026-04-13 – 2028-12-31 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06893887 · Nanjing Tianyinshan Hospital
2025-05-22 – 2028-12-15 · Hepatocellular Carcinoma(HCC)
What this study did
NCT07115550 · Huai'an First People's Hospital
2025-08-26 – 2028-08-26 · Hepatocellular Carcinoma (HCC)
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Iparomlimab And Tuvonralimab: this drugPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
DanvilostomigPhase 2Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
Lorigerlimab
Phase 2(overall)
Multispecific antibodyPD-1 x CTLA-4
not yet graded(overall)
No reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 1/2Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
AI-061Phase 1CombinationPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 544 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(157 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Iparomlimab and tuvonralimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
December 2026 (9)
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2026-12 · NCT07290010 · CT.gov ↗
What to watch
Phase 2HR-positive/HER2-negative Breast CancerRecruiting
Est. primary completion 2026-12 · NCT07396324 · CT.gov ↗
What to watch
Phase 2Biliary Tract TumorsActive not recruiting
Est. primary completion 2026-12 · NCT06892925 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4, Solid TumorsActive not recruiting
Est. primary completion 2026-12-01 · NCT06809530 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer With Liver MetastasesRecruiting
Est. primary completion 2026-12-01 · NCT06787183 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Endometrial CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT06751277 · CT.gov ↗
What to watch
Phase 2Locally Advanced Resectable Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06908382 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07271602 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07867392 · CT.gov ↗
What to watch
2027 (73)
January 2027 (1)
Phase 2Rectal Cancer PatientsRecruiting
Est. primary completion 2027-01-01 · NCT07291401 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Colorectal Cancer Liver MetastasisRecruiting
Est. primary completion 2027-02-01 · NCT06801665 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-25 · NCT06897046 · CT.gov ↗
What to watch
Phase 2Recurrent Cervical CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07172217 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-03-01 · NCT07049185 · CT.gov ↗
What to watch
Phase 2Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination DeficiencyNot yet recruiting
Est. primary completion 2027-03-30 · NCT07113964 · CT.gov ↗
What to watch
Phase 2Neoadjuvant Immunotherapy, Locally Advanced Cervical CancerActive not recruiting
Est. primary completion 2027-03-30 · NCT07205497 · CT.gov ↗
What to watch
April 2027 (5)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07139041 · CT.gov ↗
What to watch
Phase 1/2Intermediate Trophoblastic TumorRecruiting
Est. primary completion 2027-04-16 · NCT06941766 · CT.gov ↗
What to watch
Phase 2Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruiting
Est. primary completion 2027-04-30 · NCT07530445 · CT.gov ↗
What to watch
Phase 2Endometrial Adenocarcinoma, Endometrial CancerRecruiting
Est. primary completion 2027-04-30 · NCT06917092 · CT.gov ↗
What to watch
May 2027 (5)
Phase 2Bone and Soft Tissue TumorsRecruiting
Est. primary completion 2027-05-01 · NCT06939855 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma ResectableRecruiting
Est. primary completion 2027-05-01 · NCT07014150 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CancerRecruiting
Est. primary completion 2027-05-15 · NCT06951997 · CT.gov ↗
What to watch
Phase 2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2027-05-30 · NCT07005583 · CT.gov ↗
What to watch
Phase 2Breast Cancer, HR+/HER2- Breast CancerRecruiting
Est. primary completion 2027-05-31 · NCT06967103 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1/2Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2027-06 · NCT07272590 · CT.gov ↗
What to watch
Phase 2Extensive Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07083375 · CT.gov ↗
What to watch
Phase 3Ovarian Clear Cell CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT07002346 · CT.gov ↗
What to watch
Phase 2Colon Cancer, MSS/pMMR, QL1706Not yet recruiting
Est. primary completion 2027-06-30 · NCT07156682 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-06-30 · NCT07150247 · CT.gov ↗
What to watch
July 2027 (3)
Early phase / not applicableLocally Advanced Rectal Cancer (LARC), 5-12cm to Anal VergeNot yet recruiting
Est. primary completion 2027-07-01 · NCT07769853 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (GC)Not yet recruiting
Est. primary completion 2027-07-31 · NCT07045805 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC), Second Line TreatmentActive not recruiting
Est. primary completion 2027-07-31 · NCT07138885 · CT.gov ↗
What to watch
August 2027 (10)
Phase 1TNBC, Triple Negative Breast CancerRecruiting
Est. primary completion 2027-08-01 · NCT07178171 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Recruiting
Est. primary completion 2027-08-01 · NCT07070700 · CT.gov ↗
What to watch
Phase 2Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy, Consolidation ImmunotherapyRecruiting
Est. primary completion 2027-08-01 · NCT07091305 · CT.gov ↗
What to watch
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07090317 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-08-26 · NCT07115550 · CT.gov ↗
What to watch
Phase 2dMMR/MSI-H-type Rectal AdenocarcinomaActive not recruiting
Est. primary completion 2027-08-30 · NCT07160647 · CT.gov ↗
What to watch
Phase 2mCRCNot yet recruiting
Est. primary completion 2027-08-31 · NCT07116577 · CT.gov ↗
What to watch
Phase 2Advance Pancreatic CancerRecruiting
Est. primary completion 2027-08-31 · NCT07110064 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07353268 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT05487391 · CT.gov ↗
What to watch
September 2027 (9)
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07180160 · CT.gov ↗
What to watch
Phase 2AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, ImmunotherapyRecruiting
Est. primary completion 2027-09 · NCT07289997 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT07776639 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT05976568 · CT.gov ↗
What to watch
Phase 2TNBC, Triple Negative Breast CancerRecruiting
Est. primary completion 2027-09-15 · NCT07601178 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-30 · NCT06884982 · CT.gov ↗
What to watch
Phase 2Treatment of Recurrent Ovarian CancerRecruiting
Est. primary completion 2027-09-30 · NCT07286240 · CT.gov ↗
What to watch
Phase 2Neoadjuvant Treatment for Locally Advanced Cervical CancerRecruiting
Est. primary completion 2027-09-30 · NCT07286253 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2027-09-30 · NCT07509515 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07134413 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent, Cervical Adenocarcinoma, Cervical Cancer Squamous CellNot yet recruiting
Est. primary completion 2027-10-01 · NCT07141186 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT07776080 · CT.gov ↗
What to watch
November 2027 (4)
Phase 2Biliary Tract Cancer (BTC), First-line TherapyNot yet recruiting
Est. primary completion 2027-11 · NCT07129018 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07197697 · CT.gov ↗
What to watch
Phase 1DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy, Iparomlimab and Tuvonralimab InjectionRecruiting
Est. primary completion 2027-11-30 · NCT07343791 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Adenocarcinoma MetastaticRecruiting
Est. primary completion 2027-11-30 · NCT07392346 · CT.gov ↗
What to watch
December 2027 (22)
Phase 2Cervical Cancer Stage IVBNot yet recruiting
Est. primary completion 2027-12 · NCT06882447 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07082179 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07179900 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07200947 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular Carcinoma(HCC)Recruiting
Est. primary completion 2027-12-15 · NCT06893887 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-18 · NCT07286942 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2027-12-25 · NCT07342283 · CT.gov ↗
What to watch
Phase 2Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07148427 · CT.gov ↗
What to watch
Phase 2Hepatecellular Carcinoma, RALOX-HAIC(Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab …Recruiting
Est. primary completion 2027-12-30 · NCT07327788 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT07416058 · CT.gov ↗
What to watch
Phase 2Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction TherapyRecruiting
Est. primary completion 2027-12-31 · NCT07085234 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07205185 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07246317 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric CancerRecruiting
Est. primary completion 2027-12-31 · NCT07315854 · CT.gov ↗
What to watch
Phase 2ES-SCLCNot yet recruiting
Est. primary completion 2027-12-31 · NCT07349225 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, Immunotherapy, Mismatch Repair DeficiencyNot yet recruiting
Est. primary completion 2027-12-31 · NCT07369986 · CT.gov ↗
What to watch
Phase 2Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-12-31 · NCT07389629 · CT.gov ↗
What to watch
Phase 2Ovarian CancersNot yet recruiting
Est. primary completion 2027-12-31 · NCT07407452 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 AntibodyRecruiting
Est. primary completion 2027-12-31 · NCT07447570 · CT.gov ↗
What to watch
Phase 2Local Advanced Esophageal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07530549 · CT.gov ↗
What to watch
Phase 2Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H CancerRecruiting
Est. primary completion 2027-12-31 · NCT07127822 · CT.gov ↗
What to watch
Early phase / not applicableSquamous Cell Carcinoma of Head and NeckRecruiting
Est. primary completion 2027-12-31 · NCT07546383 · CT.gov ↗
What to watch
2028 (51)
January 2028 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-28 · NCT07330596 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4, TACENot yet recruiting
Est. primary completion 2028-01-30 · NCT07128251 · CT.gov ↗
What to watch
February 2028 (3)
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-02-28 · NCT07070713 · CT.gov ↗
What to watch
Phase 2Advanced Intrahepatic CholangiocarcinomaNot yet recruiting
Est. primary completion 2028-02-29 · NCT07152769 · CT.gov ↗
What to watch
Phase 2Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-02-29 · NCT06829797 · CT.gov ↗
What to watch
March 2028 (6)
Phase 3Small-cell Lung CancerNot yet recruiting
Est. primary completion 2028-03 · NCT06789796 · CT.gov ↗
What to watch
Phase 1Rectal CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT06931873 · CT.gov ↗
What to watch
Phase 1/2Recurrent or Metastatic Cervical CancerNot yet recruiting
Est. primary completion 2028-03-31 · NCT07542717 · CT.gov ↗
What to watch
Phase 2Cervical CancersRecruiting
Est. primary completion 2028-03-31 · NCT06878222 · CT.gov ↗
What to watch
Phase 2BTCNot yet recruiting
Est. primary completion 2028-03-31 · NCT07263360 · CT.gov ↗
What to watch
Phase 4Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-03-31 · NCT07502027 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Locally Advanced Nasopharyngeal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-04-30 · NCT07135804 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant ImmunotherapyNot yet recruiting
Est. primary completion 2028-05-30 · NCT07515469 · CT.gov ↗
What to watch
Phase 2Colon CancerRecruiting
Est. primary completion 2028-05-30 · NCT06949111 · CT.gov ↗
What to watch
June 2028 (9)
Phase 2Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-06-01 · NCT07733115 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07782840 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Neoadjuvant Therapy, ImmunotherapyNot yet recruiting
Est. primary completion 2028-06-15 · NCT07617818 · CT.gov ↗
What to watch
Early phase / not applicableTriple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-06-15 · NCT07187674 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2028-06-19 · NCT06936748 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2028-06-30 · NCT07256236 · CT.gov ↗
What to watch
Phase 2QL1706, ESCC, First-line TherapyNot yet recruiting
Est. primary completion 2028-06-30 · NCT07533305 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07841574 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07874438 · CT.gov ↗
What to watch
July 2028 (4)
Phase 3Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07025239 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT07595523 · CT.gov ↗
What to watch
Phase 2CancerNot yet recruiting
Est. primary completion 2028-07-09 · NCT07041788 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-07-16 · NCT07101744 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2/3MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706Recruiting
Est. primary completion 2028-08-01 · NCT07866313 · CT.gov ↗
What to watch
Phase 2Urologic NeoplasmsNot yet recruiting
Est. primary completion 2028-08-15 · NCT07741617 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic CancerNot yet recruiting
Est. primary completion 2028-09-01 · NCT07833241 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-09-20 · NCT07829874 · CT.gov ↗
What to watch
Phase 2Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy, Neoadjuvant ChemoimmunotherapyRecruiting
Est. primary completion 2028-09-23 · NCT07165847 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Head and Neck CancerRecruiting
Est. primary completion 2028-10-16 · NCT07882888 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Esophageal Squamous CarcinomaNot yet recruiting
Est. primary completion 2028-11-30 · NCT07490002 · CT.gov ↗
What to watch
December 2028 (17)
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07151209 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07452003 · CT.gov ↗
What to watch
Phase 2Uterine Cervical Neoplasms, Locally AdvancedRecruiting
Est. primary completion 2028-12-01 · NCT07646301 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Cancinoma (NPC), Nasopharyngeal CancerRecruiting
Est. primary completion 2028-12-01 · NCT06749899 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706Recruiting
Est. primary completion 2028-12-30 · NCT07372079 · CT.gov ↗
What to watch
Phase 2/3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07636226 · CT.gov ↗
What to watch
Phase 3Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)Not yet recruiting
Est. primary completion 2028-12-30 · NCT07729605 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Stage IIINot yet recruiting
Est. primary completion 2028-12-31 · NCT07315035 · CT.gov ↗
What to watch
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07400315 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07502014 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07446387 · CT.gov ↗
What to watch
Phase 2Colon Cancer, Synchronous Liver MetastasesNot yet recruiting
Est. primary completion 2028-12-31 · NCT07649473 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07673835 · CT.gov ↗
What to watch
Phase 2Resectable Hepatocellular Carcinoma With High Risk of RecurrenceRecruiting
Est. primary completion 2028-12-31 · NCT06954116 · CT.gov ↗
What to watch
Phase 2Melanoma (Skin) Stage IVRecruiting
Est. primary completion 2028-12-31 · NCT07847359 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced Pancreatic CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT07938658 · CT.gov ↗
What to watch
Phase 4PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, BevacizumabNot yet recruiting
Est. primary completion 2028-12-31 · NCT07004335 · CT.gov ↗
What to watch
2029 (17)
January 2029 (1)
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2029-01-15 · NCT07328009 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Penile CancerRecruiting
Est. primary completion 2029-02-01 · NCT07384416 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Cancer MetastaticNot yet recruiting
Est. primary completion 2029-02-10 · NCT07413601 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Ovarian CancersNot yet recruiting
Est. primary completion 2029-04 · NCT07663513 · CT.gov ↗
What to watch
May 2029 (2)
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07538193 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer Metastatic to LiverNot yet recruiting
Est. primary completion 2029-05-27 · NCT07863869 · CT.gov ↗
What to watch
June 2029 (2)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-06 · NCT05690945 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06-30 · NCT07379398 · CT.gov ↗
What to watch
July 2029 (2)
Phase 4HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-07 · NCT07668570 · CT.gov ↗
What to watch
Phase 3Local Advanced Rectal Cancer, Radiotherapy, ImmunotherapyRecruiting
Est. primary completion 2029-07-15 · NCT07686640 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07828873 · CT.gov ↗
What to watch
Phase 4Melanoma, Acral MelanomaNot yet recruiting
Est. primary completion 2029-09 · NCT07854522 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Advanced Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-10 · NCT07847671 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2RCC, Renal Cell CancerNot yet recruiting
Est. primary completion 2029-11-30 · NCT07277972 · CT.gov ↗
What to watch
December 2029 (3)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-12-01 · NCT07933016 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2029-12-31 · NCT06864013 · CT.gov ↗
What to watch
Phase 2Rectal Neoplasms MalignantNot yet recruiting
Est. primary completion 2029-12-31 · NCT07383285 · CT.gov ↗
What to watch
2030 (6)
January 2030 (1)
Early phase / not applicableTNBC, Adjuvant Therapy, Lymph Node PositiveRecruiting
Est. primary completion 2030-01-31 · NCT07622836 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Hepatecellular CarcinomaNot yet recruiting
Est. primary completion 2030-03-01 · NCT07940478 · CT.gov ↗
What to watch
August 2030 (2)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2030-08 · NCT07882056 · CT.gov ↗
What to watch
Phase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), QL1706, Lenvatinib, ChemotherapyNot yet recruiting
Est. primary completion 2030-08-01 · NCT07738159 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12 · NCT06852456 · CT.gov ↗
What to watch
Phase 3Colon CancerRecruiting
Est. primary completion 2030-12 · NCT06686576 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 3Locally Advanced Cervical CarcinomaNot yet recruiting
Est. primary completion 2032-12-31 · NCT07613567 · CT.gov ↗
What to watch

See the full readout calendar ↗